Table 1.

Patient characteristics

Patient # (protocol identifier)GSK2118436 doseSexAge, yTumor histologyBRAF mutation statusBest response and % reduction RECIST (%)
01 (5118)200 mg b.i.dF69MelanomaV600ENot restaged
05 (5119)200 mg b.i.dM52MelanomaK601EPD, 38%
08 (5120)200 mg b.i.dM45MelanomaV600EUnconfirmed PR, −53%
14 (5127)100 mg t.i.dF74Papillary thyroidV600EConfirmed PR, −37%
16 (5128)100 mg t.i.dF66CRCV600ESD
18 (5131)150 mg b.i.dM35MelanomaV600EUnconfirmed PR, −66% -
19 (5132)150 mg b.i.dF61MelanomaV600EConfirmed PR, −50%
20 (5133)200 mg b.i.dF76MelanomaV600EPD-new lesion
21 (5134)200 mg b.i.dF62MelanomaV600ESD, −22%
25 (5203)150 mg b.i.dM56MelanomaV600EPR, −54%
34 (5136)75 mg b.i.dM56MelanomaV600EUnconfirmed PR, −33%
35 (5304)150 mg b.i.dM48CRCV600ESD, 1%
40 (5305)150 mg b.i.dF57Papillary thyroidV600ESD, −10%

Abbreviations: CRC, colorectal cancer; PR, partial response, SD, stable disease; PD, progressive disease.